The Winship Cancer Institute (WCI) at Emory University is a multidisciplinary matrix center that supports, facilitates, coordinates, and centralizes cancer research, quality oncology care, education, and dissemination at Emory University and its affiliate institutions in order to reduce the burden of cancer, associated morbidity, and mortality in the state of Georgia, the Southeastern region, and the U.S. Its Director, Brian Leyland-Jones, MD, PhD, also serves as Associate Vice-President in the Woodruff Health Sciences Center and leads an expert team of Senior Leadership, Program Leaders, and Core Directors. The 152 WCI members engage in four scientific programs: Cancer Genetics and Epigenetics (CGE), Molecular Pathways and Biomarkers (MPB), Discovery and Drug Development (DDT), and Cancer Control and Population Sciences (CCPS). Shared core resources provide services in Clinical Trials, Cell Imaging and Microscopy, Biomarker Profiling, Biostatistics, and Human Tissue and Pathology. The WCI currently occupies dedicated facilities of over 350,000 nsf under the direct control of the Director. During the P20 Planning Grant period, the WCI's NCI funding grew from $9.49 million to its current mark of $25 million in NCI grants out of a total of $55.4 million in extramural, peer-reviewed cancer funding. This growth has been facilitated by the extensive recruiting of new faculty to Emory, resulting in 88 new recruits from 19 different departments across the Schools of Medicine, Public Health, Nursing, and Emory College. Other noteworthy accomplishments during this planning period have been substantial progress in clinical trials as measured by total accruals and accruals to investigator-initiated studies, and the success in team science awards, including multiple P01's, P20's, P60, the U54 Cancer Center for Nanotechnology Excellence, and a Head and Neck SPORE. The WCI has received extensive institutional support, including more than $95 million in University funding to support infrastructure and new initiatives, plus $103 million for the construction of the WCI building dedicated in 2002. Beyond funding, Emory has been committed to elevating the status of the cancer center within the University;enhancing the organizational position of the cancer center within the Woodruff Health Sciences Center;and ensuring the sustained authority of the Director. The WCI also benefits from intense support from its community partners, including the Georgia Cancer Coalition (GCC), which has provided over $28 million in support to 51 GCC Scholars among WCI members;the American Cancer Society;the CDC;and other area-based institutions, including the Georgia Institute of Technology and Morehouse School of Medicine. Developmental funds are requested for a Transgenic Mouse and Gene Targeting Core and essential Bioinformatics technology. The WCI is well-positioned to continue to advance its progress as it pursues NCI-designation as a cancer center, and to fulfill its mission to reduce the burden of cancer throughout the state of Georgia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA138292-01S2
Application #
7939279
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2009-09-30
Project End
2012-09-29
Budget Start
2009-09-30
Budget End
2012-09-29
Support Year
1
Fiscal Year
2009
Total Cost
$50,000
Indirect Cost
Name
Emory University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Cassidy, Richard J; Zhang, Xinyan; Switchenko, Jeffrey M et al. (2018) Health care disparities among octogenarians and nonagenarians with stage III lung cancer. Cancer 124:775-784
Xiao, Canhua; Beitler, Jonathan J; Higgins, Kristin A et al. (2018) Differential regulation of NF-kB and IRF target genes as they relate to fatigue in patients with head and neck cancer. Brain Behav Immun 74:291-295
Jhaveri, Jaymin; Rayfield, Lael; Liu, Yuan et al. (2018) Impact of intensity modulated radiation therapy on survival in anal cancer. J Gastrointest Oncol 9:618-630
Jhaveri, Jaymin; Chowdhary, Mudit; Zhang, Xinyan et al. (2018) Does size matter? Investigating the optimal planning target volume margin for postoperative stereotactic radiosurgery to resected brain metastases. J Neurosurg :1-7
Chowdhary, Mudit; Switchenko, Jeffrey M; Press, Robert H et al. (2018) Post-treatment neutrophil-to-lymphocyte ratio predicts for overall survival in brain metastases treated with stereotactic radiosurgery. J Neurooncol 139:689-697
Bilen, Mehmet Asim; Dutcher, Giselle Marie Almeida; Liu, Yuan et al. (2018) Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. Clin Genitourin Cancer 16:e563-e575
Morgan, T M; Wang, X; Qian, X et al. (2018) Measurement of circulating tumor cells in squamous cell carcinoma of the head and neck and patient outcomes. Clin Transl Oncol :
Lin, Songbai; Han, Yiran; Jenkin, Kayte et al. (2018) Lysophosphatidic Acid Receptor 1 Is Important for Intestinal Epithelial Barrier Function and Susceptibility to Colitis. Am J Pathol 188:353-366
Zhu, Dan; Osuka, Satoru; Zhang, Zhaobin et al. (2018) BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation. Cancer Cell 33:1004-1016.e5
Bekhbat, Mandakh; Chu, Karen; Le, Ngoc-Anh et al. (2018) Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression. Psychoneuroendocrinology 98:222-229

Showing the most recent 10 out of 331 publications